Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (9112)	5/6/1998 1:58:00 PM
From: RealMuLan	Respond to of 120523

IMMU from Briefing.com 12:23 ET Immunomedics (IMMU) 5 7/8 +3/4 (+15%): Company reported that two of its recipients of radioactively labeled antibodies -- both deemed terminal when referred for experimental therapy -- will soon reach their third anniversaries in complete remission following receipt of the company's proprietary isotope-labeled antibodies. The first patient, a 73-year-old New Jersey woman, enjoys complete remission from terminal ovarian cancer resistant to carboplatin, cytoxan and taxol. What is that, nine or ten press releases in two days from companies with a cancer drug. In a sense, this frenzy is even worse than the one in Internet stocks. How many companies do you think will actually come up with an effective cancer treatment vs how many of the Internet companies with trumped up press releases will experience extremely robust revenue growth over the next few years? So, you ask, "Why do we keep mentioning these stocks?" Because they are "In Play," not b/c we think that they are worth a damn.